THER Stock Overview
A commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Theralink Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0019 |
| 52 Week Low | US$0.000001 |
| Beta | 20.09 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -91.67% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.93% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| THER | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -2.4% |
| 1Y | -91.7% | -2.7% | 23.3% |
Return vs Industry: THER underperformed the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: THER underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| THER volatility | |
|---|---|
| THER Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: THER's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine THER's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 16 | n/a | www.theralink.com |
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments.
Theralink Technologies, Inc. Fundamentals Summary
| THER fundamental statistics | |
|---|---|
| Market cap | US$615.15k |
| Earnings (TTM) | -US$13.50m |
| Revenue (TTM) | US$635.45k |
1.0x
P/S Ratio0.0x
P/E RatioIs THER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THER income statement (TTM) | |
|---|---|
| Revenue | US$635.45k |
| Cost of Revenue | US$245.25k |
| Gross Profit | US$390.20k |
| Other Expenses | US$13.89m |
| Earnings | -US$13.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0022 |
| Gross Margin | 61.41% |
| Net Profit Margin | -2,124.13% |
| Debt/Equity Ratio | -39.5% |
How did THER perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 11:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Theralink Technologies, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|